United Pharmaceutical Establishment, commonly referred to as UPE, is a leading player in the pharmaceutical industry, headquartered in Saudi Arabia (SA). Established in 1993, UPE has made significant strides in the development and distribution of high-quality pharmaceutical products across the Middle East and North Africa (MENA) region. Specialising in a diverse range of therapeutic areas, UPE is renowned for its innovative formulations and commitment to quality. The company’s core offerings include prescription medications, over-the-counter products, and specialised healthcare solutions, all designed to meet the evolving needs of patients and healthcare providers. With a strong market presence and a reputation for excellence, United Pharmaceutical Establishment has achieved numerous accolades, solidifying its position as a trusted name in the pharmaceutical sector.
How does United Pharmaceutical Establishment's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
United Pharmaceutical Establishment's score of 20 is lower than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
United Pharmaceutical Establishment, headquartered in Saudi Arabia, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the organisation. This lack of data suggests that United Pharmaceutical Establishment may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the pharmaceutical industry increasingly prioritises sustainability, it will be essential for the company to consider developing and communicating its climate commitments to align with industry standards and expectations.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
United Pharmaceutical Establishment has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
